Steven Cohen's CPRX Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 425,865 shares of Catalyst Pharmaceuticals, Inc. (CPRX) worth $10.54 M, representing 0.01% of the portfolio. First purchased in 2014-Q4, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in CPRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2015, adding 3.07 M shares. Largest reduction occurred in Q2 2015, reducing 3.1 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Catalyst Pharmaceuticals (CPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Catalyst Pharmaceuticals (CPRX) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +425,865 | New Buy | 425,865 | $24.76 |
| Q3 2024 | -618,296 | Sold Out | 0 | $0.00 |
| Q2 2024 | +200,370 | Add 47.94% | 618,296 | $15.49 |
| Q1 2024 | -78,665 | Reduce 15.84% | 417,926 | $15.94 |
| Q4 2023 | +300,280 | Add 152.96% | 496,591 | $16.81 |
| Q3 2023 | +196,311 | New Buy | 196,311 | $11.69 |
| Q2 2023 | -1,470 | Sold Out | 0 | $0.00 |
| Q1 2023 | +1,470 | New Buy | 1,470 | $16.58 |
| Q4 2020 | -50,000 | Sold Out | 0 | $0.00 |
| Q3 2020 | +50,000 | New Buy | 50,000 | $2.98 |
| Q2 2017 | -877,266 | Sold Out | 0 | $0.00 |
| Q1 2017 | -1.4 M | Reduce 61.40% | 877,266 | $1.95 |
| Q4 2016 | -94,148 | Reduce 3.98% | 2.27 M | $1.05 |
| Q2 2016 | +103,388 | Add 4.57% | 2.37 M | $0.71 |
| Q1 2016 | -13,347 | Reduce 0.59% | 2.26 M | $1.17 |
| Q4 2015 | +70,659 | Add 3.20% | 2.28 M | $2.45 |
| Q3 2015 | -1.26 M | Reduce 36.31% | 2.21 M | $3.00 |
| Q2 2015 | -3.1 M | Reduce 47.26% | 3.46 M | $4.13 |
| Q1 2015 | +3.07 M | Add 87.66% | 6.57 M | $4.33 |
| Q4 2014 | +3.5 M | New Buy | 3.5 M | $2.97 |
Steven Cohen's Catalyst Pharmaceuticals Investment FAQs
Steven Cohen first purchased Catalyst Pharmaceuticals, Inc. (CPRX) in Q4 2014, acquiring 3,500,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Catalyst Pharmaceuticals, Inc. (CPRX) for 21 quarters since Q4 2014.
Steven Cohen's largest addition to Catalyst Pharmaceuticals, Inc. (CPRX) was in Q4 2014, adding 3,500,000 shares worth $10.4 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 425,865 shares of Catalyst Pharmaceuticals, Inc. (CPRX), valued at approximately $10.54 M.
As of the Q1 2026 filing, Catalyst Pharmaceuticals, Inc. (CPRX) represents approximately 0.01% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Catalyst Pharmaceuticals, Inc. (CPRX) was 6,568,000 shares, as reported at the end of Q1 2015.